Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC for Cognition and Negative Symptoms in Schizophrenia
NCT02505477Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2017
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of acetylcysteine in schizophrenia, schizoaffective disorder, sponsored by University of California, Los Angeles. Started Feb 2017; status: completed.
02
Drugs
acetylcysteine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02505477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505477.